PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.

In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) treatment induces granulocytic maturation and complete remission of leukemia. microRNAs are known to be critical players in the formation of the leukemic phenotype. In this study, we report downregulation of the miR-181a/b gene cluster in APL blasts and NB4 leukemia cells upon ATRA treatment as a key event in the drug response. We found that miR-181a/b expression was activated by the PML/RARα oncogene in cells and transgenic knock-in mice, an observation confirmed and extended by evidence of enhanced expression of miR-181a/b in APL patient specimens. RNA interference (RNAi)-mediated attenuation of miR-181a/b expression in NB4 cells was sufficient to reduce colony-forming capacity, proliferation, and survival. Mechanistic investigations revealed that miR-181a/b targets the ATRA-regulated tumor suppressor gene RASSF1A by direct binding to its 3'-untranslated region. Enforced expression of miR-181a/b or RNAi-mediated attenuation of RASSF1A inhibited ATRA-induced granulocytic differentiation via regulation of the cell-cycle regulator cyclin D1. Conversely, RASSF1A overexpression enhanced apoptosis. Finally, RASSF1A levels were reduced in PML/RARα knock-in mice and APL patient samples. Taken together, our results define miR-181a and miR-181b as oncomiRs in PML/RARα-associated APL, and they reveal RASSF1A as a pivotal element in the granulocytic differentiation program induced by ATRA in APL.

[1]  J. Reilly,et al.  Aberrant methylation of the negative regulators RASSFIA, SHP‐1 and SOCS‐1 in myelodysplastic syndromes and acute myeloid leukaemia , 2005, British journal of haematology.

[2]  Stefano Volinia,et al.  miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. , 2011, Blood.

[3]  Bob Löwenberg,et al.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. , 2008, Blood.

[4]  C. Croce,et al.  MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia , 2007, Oncogene.

[5]  Alessandro Fatica,et al.  A Minicircuitry Comprised of MicroRNA-223 and Transcription Factors NFI-A and C/EBPα Regulates Human Granulopoiesis , 2005, Cell.

[6]  F. Végran,et al.  STAT3 activation , 2013, JAK-STAT.

[7]  Fang Wang,et al.  Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. , 2006, Biochemical and biophysical research communications.

[8]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[9]  J. Minna,et al.  The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation , 2002, Molecular and Cellular Biology.

[10]  Xiuping Liu,et al.  Functional analysis of microRNAs in human hepatocellular cancer stem cells , 2011, Journal of cellular and molecular medicine.

[11]  M. Caligiuri,et al.  Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. , 2013, Blood.

[12]  M. Caligiuri,et al.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. , 2012, Blood.

[13]  Y. Pekarsky,et al.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.

[14]  C. Croce,et al.  CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control , 2006, Proceedings of the National Academy of Sciences.

[15]  Elodie Portales-Casamar,et al.  Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. , 2009, Blood.

[16]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[17]  D. Tenen,et al.  Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. , 2013, Blood.

[18]  D. Tenen,et al.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia , 2014, Leukemia.

[19]  K. Ghoshal,et al.  TGFβ mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3 , 2009, Oncogene.

[20]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[21]  S. Collins,et al.  Terminal Differentiation of Human Promyelocytic Leukemic Cells in Primary Culture in Response to Retinoic Acid , 1981 .

[22]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[23]  F. Lo‐Coco,et al.  A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes , 2009, Oncogene.

[24]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[25]  M. Yi,et al.  RASSF1A suppresses melanoma development by modulating apoptosis and cell‐cycle progression , 2011, Journal of cellular physiology.

[26]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[27]  A. Bell,et al.  Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis* , 2000, The Journal of Biological Chemistry.

[28]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[29]  Daniel G Tenen,et al.  C/EBPβ: a major PML–RARA‐responsive gene in retinoic acid‐induced differentiation of APL cells , 2003, The EMBO journal.

[30]  T. Triche,et al.  Retinoid-induced G1 Arrest and Differentiation Activation Are Associated with a Switch to Cyclin-dependent Kinase-activating Kinase Hypophosphorylation of Retinoic Acid Receptor α* , 2002, The Journal of Biological Chemistry.

[31]  Jian-yong Li,et al.  miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. , 2012, Carcinogenesis.

[32]  A. Fatica,et al.  Role of microRNAs in myeloid differentiation. , 2008, Biochemical Society transactions.

[33]  Mark M. Davis,et al.  miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection , 2007, Cell.

[34]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[35]  F. Latif,et al.  Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.

[36]  J. Licht,et al.  Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. , 1999, Blood.

[37]  Youhong Liu,et al.  Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low‐dose arsenite‐induced cell proliferation , 2010, Journal of cellular biochemistry.

[38]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[39]  T Chaplin,et al.  MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis , 2007, Leukemia.

[40]  Kevin Struhl,et al.  STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. , 2010, Molecular cell.

[41]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[42]  M. Omrani,et al.  Intact expression status of RASSF1A in acute myeloid leukemia , 2013, Medical Oncology.

[43]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[44]  J. Licht.  Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? , 2006, Cancer cell.

[45]  G. Behre,et al.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. , 2008, Blood.

[46]  J. Chen,et al.  MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets , 2014, Oncogene.

[47]  Daniel G Tenen,et al.  Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. , 2010, Blood.

[48]  Michael A McDevitt,et al.  Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation , 2010, Leukemia & lymphoma.

[49]  D. Tenen,et al.  Proteomic analysis of acute promyelocytic leukemia: PML‐RARα leads to decreased phosphorylation of OP18 at serine 63 , 2006, Proteomics.

[50]  R. Garzon,et al.  MicroRNAs: new players in acute myeloid leukaemia , 2009, British Journal of Cancer.

[51]  S. Bohlander,et al.  C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. , 2010, Blood.

[52]  T. Ley,et al.  High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. , 2003, Blood.